Chin Pan

USPTO Granted Patents = 16 (Patent Applications = 13)

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 10 (Patent Applications = 3)

Average Co-Inventor Count = 4.8

ph-index = 7

Forward Citations = 163(Granted Patents)

Location History:

Redwood City, CA (US) (2015 - 2019)
Los Altos, CA (US) (2005 - 2021)

Company Filing History:

Bristol-Myers Squibb Compnay

patents

3 out of 1,624

E. R. Squibb Sons, Inc.

patents

4. 2 out of 18

Oxford Biotherapeutics Ltd

patents

where one patent can have more than one assignee

Years Active: 2005-2021

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11104739 - Combination therapy using an anti-fucosyl-GM1 antibody and an anti-CD137 antibody (2021-08-31),

2. 10428151 - Treatment of hematologic malignancies with an anti-CXCR4 antibody (2019-10-01),

3. 9932411 - Antibodies (2018-04-03),

4. 9505845 - Treating lung cancer using human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) (2016-11-29),

5. 9217033 - Monoclonal antibodies against Glypican-3 (2015-12-22),

6. 9186416 - Immunoconjugates, compositions for making them, and methods of making and use (2015-11-17),

7. 9102738 - Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) (2015-08-11),

8. 8852599 - Immunoconjugates, compositions for making them, and methods of making and use (2014-10-07),

9. 8680247 - Monoclonal antibodies against glypican-3 (2014-03-25),

10. 8420084 - Fully human antibodies specific to CADM1 (2013-04-16),

11. 8222375 - Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies (2012-07-17),

12. 8124738 - Human monoclonal antibodies to CD70 (2012-02-28),

13. 8097703 - CD19 antibodies and their uses (2012-01-17),

14. 7771962 - CD10-activated prodrug compounds (2010-08-10),

15. 7304032 - CD-10 activated prodrug compounds (2007-12-04),

Title: Innovations and Contributions of Inventor Chin Pan

Introduction

Chin Pan is a notable inventor based in Los Altos, California, with a remarkable portfolio of 16 patents. His work primarily focuses on innovative therapies for treating various cancers, showcasing his commitment to advancing medical science.

Latest Patents

One of Chin Pan's latest patents is titled "Combination therapy using an anti-fucosyl-GM1 antibody and an anti-CD137 antibody." This patent provides a combination therapy for treating subjects afflicted with lung cancer, involving the administration of both an anti-fucosyl-GM1 antibody and an anti-CD137 antibody. Another significant patent is "Treatment of hematologic malignancies with an anti-CXCR4 antibody." This disclosure presents human monoclonal antibodies that specifically bind to CXCR4 with high affinity. It also outlines a method for treating subjects with CXCR4-expressing cancers, such as multiple myeloma and acute myeloid leukemia, using a therapeutically effective amount of an anti-CXCR4 antibody.

Career Highlights

Chin Pan has made significant contributions to the field of biotechnology through his work at prominent companies. He has been associated with Medarex Inc. and Bristol-Myers Squibb Company, where he has played a crucial role in developing innovative therapies.

Collaborations

Chin Pan has collaborated with notable professionals in his field, including Jonathan Alexander Terrett and Li-Sheng Lu. Their combined expertise has contributed to the advancement of therapeutic innovations.

Conclusion

Chin Pan's contributions to cancer treatment through his innovative patents and collaborations highlight his significant impact on medical research and biotechnology. His work continues to inspire advancements in therapeutic approaches for various malignancies.

This text is generated by artificial intelligence and may not be accurate.